Company Filing History:
Years Active: 1999-2006
Title: The Innovative Contributions of Kim M. Berger
Introduction
Kim M. Berger, an accomplished inventor based in Lafayette, California, is recognized for her groundbreaking work in the realm of biotechnology. With a portfolio of five patents, she has made significant contributions to the understanding and treatment of hepatitis C virus (HCV). Her innovative approaches have led to advancements in vaccine development and therapeutic strategies.
Latest Patents
Among her latest patents, Kim M. Berger's work focuses on antibodies to hepatitis C virus asialoglycoproteins. Her research involves the expression of two hepatitis C virus envelope proteins, E1 and E2, without sialylation. This innovative recombinant expression, conducted in lower eukaryotes or in mammalian cells with blocked terminal glycosylation, yields proteins that closely resemble native HCV glycoproteins. Furthermore, when isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles, which are crucial for vaccine development.
Career Highlights
Throughout her career, Kim has held pivotal positions in prominent institutions, including Chiron Corporation and Novartis Vaccines & Diagnostics GmbH. Her work at these organizations has significantly advanced the field of infectious disease research, particularly in relation to hepatitis C.
Collaborations
Collaboration has been a key aspect of Kim M. Berger's career. She has worked alongside esteemed colleagues such as Robert O. Ralston and Frank I. Marcus, contributing to a range of projects that aim to enhance the efficacy of vaccines and therapeutic interventions against viral infections.
Conclusion
Kim M. Berger's innovative contributions to the field of biotechnology position her as a leading inventor in the fight against hepatitis C. Her patents and collaborative efforts continue to shape the landscape of vaccine development, showcasing her dedication to improving global health outcomes. As research progresses, her ongoing work promises to lead to further breakthroughs in the understanding and treatment of viral infections.